Back to top
more

Celgene Corporation (CELG)

(Delayed Data from NSDQ)

$96.88 USD

96.88
5,654,306

+1.67 (1.75%)

Updated May 3, 2019 04:00 PM ET

After-Market: $96.84 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

Mallinckrodt's Stannsoporfin Gets Complete Response Letter

Mallinckrodt's (MNK) pipeline candidate, Stannsoporfin gets a Complete Response Letter from the FDA.

    Kinjel Shah headshot

    Large-Cap Pharma Rebounds: 2 Stocks to Boost Your Portfolio

    The large-cap pharma industry is on track to recovery. Here are two stocks from the space that investors may consider betting on.

      Alnylam Completes Enrollment in Phase III Givosiran Study

      Alnylam Pharmaceuticals (ALNY) completes enrollment in the phase III ENVISION study ahead of schedule of its pipeline candidate, givosiran.

        Infinity Focuses on Developing IPI-549 for Solid Tumors

        Infinity Pharmaceuticals (INFI) aims at developing its pipeline candidate, IPI-549.

          Japan Nods to AstraZeneca's Tagrisso for First-Line NSCLC

          AstraZeneca (AZN) receives approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the label expansion of Tagrisso.

            Is Celgene Set to See Improved Results in the Second Half?

            After a series of pipeline setbacks, things are looking better for biotech bigwig Celgene (CELG) with positive data read-outs and an increase in guidance.

              Novo Nordisk Buys Ziylo to Develop Glucose Responsive Insulin

              Novo Nordisk A/S (NVO) acquires Ziylo Ltd. to speed up the development of glucose responsive insulins in a deal that could exceed $800 million.

                Supriyo Bose headshot

                Top 5 ROE Picks on Optimism Over Resolution of Trade Dispute

                ROE is often used to compare the profitability of a company with other firms in the industry - the higher, the better.

                  Geron's Growth Depends on Continuation of Imetelstat Studies

                  Investors continue to focus on development of Geron's (GERN) sole pipeline candidate, imetelstat. However, competition is rife with other companies developing treatments for similar indications.

                    John Blank headshot

                    Turkey Drives Up Worry: Global Week Ahead

                    The Turkish Lira rout that started last week is the big story for this coming week. In turn, U.S. and European earnings seasons are winding down.

                      Ligand (LGND) Proposes to Buy U.K.'s Drug Discovery Biotech

                      Ligand (LGND) makes an offer to acquire U.K.-based drug discovery biotech Vernalis to drive the same platform in its portfolio.

                        Corcept (CORT) Earnings and Revenues Miss Estimates in Q2

                        Corcept's (CORT) earnings and revenues lag estimates in Q2. Meanwhile, the company posts positive interim data from phase I/II study on its pipeline candidate relacorilant.

                          Prothena (PRTA) Q2 Earnings Lag Estimates, Pipeline in Focus

                          Prothena (PRTA) posts wider-than-expected loss in the second quarter. With the failure of lead drug, NEOD001, the focus is now mainly on its mid-stage candidate, prasinezumab.

                            The Zacks Analyst Blog Highlights: Caterpillar, BHP Billiton and Celgene

                            The Zacks Analyst Blog Highlights: Caterpillar, BHP Billiton and Celgene

                              John Blank headshot

                              Quiet in August: Global Week Ahead

                              We are now in a quiet period for the equity markets. August is where many traders take vacations, and daily volume is relatively light.

                                Prothena (PRTA) Q2 Earnings: Is a Disappointment in Store?

                                Prothena's (PRTA) Q2 results are likely to reflect pipeline updates along with progress with its restructuring plan.

                                  bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Miss

                                  bluebird (BLUE) incurs Q2 loss on account of higher expenses and lower revenues. Nevertheless, the pipeline progress looks encouraging.

                                    Agios (AGIO) Q2 Loss Narrows, Revenues Surpass Estimates

                                    Agios (AGIO) incurs narrower-than-expected loss in Q2. Additionally, higher license and collaboration/milestone fees lead to a significant year-over-year rise in revenues.

                                      Regeneron Pharmaceuticals (REGN) Jumps: Stock Rises 7%

                                      Regeneron Pharmaceuticals (REGN) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.

                                        Zacks.com featured highlights include: Celgene, Progressive, T. Rowe Price, AMC and Celanese

                                        Zacks.com featured highlights include: Celgene, Progressive, T. Rowe Price, AMC and Celanese

                                          Supriyo Bose headshot

                                          Top 5 ROE Picks as Q2 Earnings Shine Despite Trade War Woes

                                          ROE is often used to compare the profitability of a company with other firms in the industry - the higher, the better.

                                            The Zacks Analyst Blog Highlights: Celgene, Exxon Mobil, Berkshire Hathaway, Phillips 66 and VMware

                                            The Zacks Analyst Blog Highlights: Celgene, Exxon Mobil, Berkshire Hathaway, Phillips 66 and VMware

                                              Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q2, Gilead's CEO to Exit

                                              Impressive second-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.

                                                Mark Vickery headshot

                                                Top Stock Reports for Celgene, Exxon Mobil & Berkshire Hathaway

                                                The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Celgene (CELG), Exxon Mobil (XOM) and Berkshire Hathaway (BRK.B).

                                                  What's in the Cards for Agios (AGIO) Stock in Q2 Earnings?

                                                  On Agios' (AGIO) second-quarter 2018 conference call, investor focus is likely to be on the launch preparations of the company's newly FDA approved leukemia drug, Tibsovo.